Update in thrombosis: answers to perplexing questions.
Recent clinical trials are answering some of the perplexing clinical questions about venous thromboembolism (VTE), such as the length and intensity of anticoagulation needed to prevent recurrence. We review some of these clinical trials and their implications for physicians and patients.
Federman
Daniel G
DG
Department of Medicine, Section of General Medicine, Firm Chief, VA Connecticut Health Care System, West Haven, CT, USA. daniel.federman@med.va.gov
Brescia
Gina R
GR
Moriarty
John P
JP
Haskell
Sally G
SG
Krishnamurthy
Raj
R
Kirsner
Robert S
RS
D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005165:Factor V; D006801:Humans; D012307:Risk Factors; D055502:Secondary Prevention; D013923:Thromboembolism / Q000188:drug therapy* / Q000235:genetics; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000235:genetics; D014859:Warfarin / Q000008:administration & dosage / Q000627:therapeutic use*
D000925:Anticoagulants; C095381:factor V Leiden; D014859:Warfarin; D005165:Factor V